[1] Kim H S, Kim J H, Ji W K, et al. Chemotherapy in Elderly Patients with Gastric Cancer[J]. J Cancer, 2016, 7(1):88-94.
[2] Eisenhauer E A, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)[J]. Gan to Kagaku Ryoho Cancer & Chemotherapy, 2008, 45(2):228-247.
[3] Trumper M, Ross P J, Cunningham D, et al. Efficacy and tolerability of chemotherapy in elderly patients with advanced oesophago-gastric cancer: A pooled analysis of three clinical trials[J]. Euro J Cancer, 2006, 42(7):827-834.
[4] Jatoi A, Foster N R, Egner J R, et al. Older versus younger patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction, and stomach: a pooled analysis of eight consecutive North Central Cancer Treatment Group (NCCTG) trials[J]. Inter J Oncology, 2010, 36(3):601-606.
[5] Vincenzi B, Spalletta B, La C A, et al. Weekly oxaliplatin, 5-fluorouracil and folinic acid (OXALF) as first-line chemotherapy for elderly patients with advanced gastric cancer: results of a phase II trial[J]. BMC Cancer, 2006, 6(1):125.
[6] Choi I S, Oh D Y, Kim B S, et al. Oxaliplatin, 5-FU, folinic acid as first-line palliative chemotherapy in elderly patients with metastatic or recurrent gastric cancer[J]. Cancer Research & Treatment, 2007, 39(39):99-103.
[7] Liu Z F, Guo Q S, Zhang X Q, et al. Biweekly oxaliplatin in combination with continuous infusional 5-fluorouracil and leucovorin (modified FOLFOX-4 regimen) as first-line chemotherapy for elderly patients with advanced gastric cancer[J]. Am J Clin Oncology, 2008, 31(3):259-263.
[8] Catalano V, Bisonni R, Graziano F, et al. A phase Ⅱ study of modified FOLFOX as first-line chemotherapy for metastatic gastric cancer in elderly patients with associated diseases[J]. Gastric Cancer, 2013,16(3):411-419.